Pfizer Inc. (NYSE:PFE–Get Rating) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totalling 57,670,000 shares, a decrease of 15.2% from the April 30th total of 67,990,000 shares. Based on an average daily trading volume, of 28,010,000 shares, the days-to-cover ratio is presently 2.1 days.
Shares ofNYSE:PFEopened at $53.04 on Wednesday. The firm has a 50 day moving average of $51.41 and a 200-day moving average of $52.41. The stock has a market capitalization of $297.60 billion, a PE ratio of 12.17, a PEG ratio of 0.66 and a beta of 0.76. Pfizer has a 12 month low of $38.47 and a 12 month high of $61.71. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43.
Get Pfizer alerts:
Pfizer (NYSE:PFE–Get Rating) last released its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.66 by ($0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The company had revenue of $25.66 billion for the quarter, compared to analyst estimates of $24.73 billion. During the same quarter in the prior year, the company earned $0.93 earnings per share. Pfizer’s revenue for the quarter was up 76.8% compared to the same quarter last year. On average, research analysts predict that Pfizer will post 6.6 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 10th. Stockholders of record on Friday, May 13th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date is Thursday, May 12th. Pfizer’s dividend payout ratio is currently 36.70%.
Several brokerages have recently issued reports on PFE. SVB Leerink began coverage on Pfizer in a research note on Monday, May 23rd. They issued a “market perform” rating and a $55.00 price objective for the company. Barclays set a $52.00 price objective on Pfizer in a research note on Tuesday, May 17th. JPMorgan Chase & Co. set a $57.00 price objective on Pfizer in a research note on Tuesday, May 3rd. Mizuho reduced their price objective on Pfizer from $56.00 to $55.00 in a research note on Thursday, February 10th. Finally,StockNews.comupgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 19th. Eleven research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of “Buy” and a consensus price target of $57.00.
In related news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the firm’s stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the sale, the executive vice president now owns 38,146 shares of the company’s stock, valued at $1,907,300. The sale was disclosed in a filing with the SEC, which is available throughthe SEC website. Also, SVPJennifer B. Damicosold 4,000 shares of the firm’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $50.50, for a total value of $202,000.00. Following the sale, the senior vice president now directly owns 15,064 shares in the company, valued at approximately $760,732. The disclosure for this sale can be foundhere. 0.05% of the stock is currently owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. OLD Mission Capital LLC bought a new position in Pfizer during the third quarter valued at about $291,000. Morgan Stanley boosted its position in Pfizer by 3.4% during the second quarter. Morgan Stanley now owns 47,894,080 shares of the biopharmaceutical company’s stock worth $1,875,532,000 after purchasing an additional 1,582,052 shares during the period. Center for Financial Planning Inc. boosted its position in Pfizer by 1.9% during the third quarter. Center for Financial Planning Inc. now owns 17,073 shares of the biopharmaceutical company’s stock worth $734,000 after purchasing an additional 313 shares during the period. New World Advisors LLC bought a new position in Pfizer during the third quarter worth about $292,000. Finally, EagleClaw Capital Managment LLC boosted its position in Pfizer by 2.1% during the third quarter. EagleClaw Capital Managment LLC now owns 29,959 shares of the biopharmaceutical company’s stock worth $1,287,000 after purchasing an additional 625 shares during the period. Institutional investors own 66.50% of the company’s stock.
Pfizer Company Profile(Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
source：defenseworld
Comments